12,372 trials
Psoriasis
Primary: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 — 0; 80.6 Percentage of participants…
Endometriosis
Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 52.1; 78.2; 32.6; 64.4 percentage of participants
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy) — 415.8; 355.9; 117.2…
PONV
Primary: Number of Participants With Complete Response — 78; 54 Participants — p=0.033
TTR-mediated Amyloidosis · Amyloidosis, Hereditary · Amyloid Neuropathies, Familial
Primary: Modified Neuropathy Impairment Score +7 (mNIS+7) — -6.03; 27.96 score on a scale — p=<0.0000001
Irritable Bowel Syndrome
Primary: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores — 23.9…
Prostate Cancer
Primary: Overall Survival — 87; 86 percentage of probability of survival — p=0.70
Anogenital Human Papilloma Virus Infection · Condyloma Acuminata
Primary: Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection — 0.3; 1.9 Cases per 100 person-years of follow-up — p=<0.001
TBI Depression
Primary: Average Depression Score Using the Hamilton Depression (HAM-D) 17 Scale — 23.154; 23.076; 13.154; 12.706 units on a scale
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12 — -20.39; -59.75 percent change — p=<0.0001
Hypercholesterolemia · Mixed Dyslipidemia · Type 2 Diabetes
Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — -0.84; -64.98 percent change — p=<0.0001
Contraception · Bleeding
Primary: Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries — 7; 12 days — p=0.002
Plaque Psoriasis
Primary: Treatment Success Assessed by IGA — 60.8; 63.2; 56.0 Percentage of Participants — p=0.3520
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Duration of Overall Survival (OS) — 12.87; 9.99; 10.28; 10.25 months
Hereditary Angioedema (HAE)
Primary: Normalized Number of Angioedema Attacks Per Month in a Treatment Period — 1.2; 0.7 Angioedema attacks per month — p=0.03